Japan’s Matsushita Develops New DNA Technology For Drug Response
This article was originally published in PharmAsia News
Executive Summary
Matsushita Electric Industrial of Japan reports it has developed a technology that identifies DNA sequence variations electronically for predicting responses to drugs. The system dissolves artificial DNA in a solution instead of attaching it to an electrode, enabling technicians to predict an individual's response to drugs and risk of developing a particular disease. Matsushita refers to the technology as "single nucleotide polymorphisms." (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.